Johnson & Johnson on Tuesday boosted its full-year adjusted profit forecast, as multi-billion dollar sales of its cancer drugs Darzalex and Imbruvica helped it beat estimates for third-quarter profit.
Source:: Reuters – Business News
Newswire
- [ July 16, 2026 ] AST SpaceMobile (NASDAQ: ASTS) Stock Analysis: Building World’s First Space-Based Broadband Provider Arena Signals
- [ July 14, 2026 ] GameStop (NYSE: GME) Stock Analysis: Profitable Turnaround — Is Ryan Cohen This Generation’s Warren Buffett? Arena Signals
- [ July 14, 2026 ] Quantum (NASDAQ: QMCO) Stock Analysis: Rebuilding the Data Infrastructure Company for the AI Era Arena Signals
- [ July 14, 2026 ] Expensify (NASDAQ: EXFY) Stock Analysis: Building the AI-Native Financial Superapp for Business Spending Arena Signals
- [ July 14, 2026 ] 3D Systems (NYSE: DDD) Stock Analysis: “Med tech, dental, and aerospace and defense, are rapidly adopting 3D printing as a core manufacturing method.” Arena Signals
- [ July 14, 2026 ] PagerDuty (NYSE: PD) Stock Analysis: Becoming the AI Control Plane for Enterprise Operations Arena Signals
- [ July 14, 2026 ] Xometry (NASDAQ: XMTR) Stock Analysis: Building the AI-Native Operating System for Global Manufacturing Arena Signals
- [ July 10, 2026 ] Wrap Technologies (NASDAQ: WRAP) Stock Analysis: Transforming into AI-Driven Public Safety Platform Arena Signals
- [ July 10, 2026 ] Rivian (NASDAQ: RIVN) Stock Analysis: From EV Manufacturer to AI-Powered Mobility Platform Arena Signals
- [ July 9, 2026 ] nLIGHT (NASDAQ: LASR) Stock Analysis: $627M Pentagon Award Validates the Next Phase of Growth Arena Signals
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.